Advertisement

Topics

Hyperuricemia - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Hyperuricemia - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 63-page report is available in PDF from $2000.

Hyperuricemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Hyperuricemia - Pipeline Review, H1 2015’, provides an overview of the Hyperuricemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperuricemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperuricemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperuricemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperuricemia Overview 7
Therapeutics Development 8
Pipeline Products for Hyperuricemia - Overview 8
Pipeline Products for Hyperuricemia - Comparative Analysis 9
Hyperuricemia - Therapeutics under Development by Companies 10
Hyperuricemia - Therapeutics under Investigation by Universities/Institutes 11
Hyperuricemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperuricemia - Products under Development by Companies 15
Hyperuricemia - Products under Investigation by Universities/Institutes 16
Hyperuricemia - Companies Involved in Therapeutics Development 17
AstraZeneca PLC 17
CymaBay Therapeutics, Inc. 18
Kissei Pharmaceutical Co., Ltd. 19
LG Life Sciences, Ltd. 20
Nippon Chemiphar Co., Ltd. 21
Polaris Pharmaceuticals, Inc. 22
Takeda Pharmaceutical Company Limited 23
Teijin Pharma Limited 24
Hyperuricemia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
arhalofenate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
febuxostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
febuxostat XR - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
JPH-367 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
KGO-2142 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
KGO-2173 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
KUX-1151 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LC-350189 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NC-2500 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pegadricase - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RDEA-3170 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
XEN-102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Hyperuricemia - Recent Pipeline Updates 51
Hyperuricemia - Dormant Projects 54 For more information open Hyperuricemia - Pipeline Review, H1 2015.

SKU: GMDHC6615IDB

Original Article: Hyperuricemia - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Hyperuricemia - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...